These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 17118836)

  • 1. Radioiodine treatment for malignant thyroid disease.
    Berg G
    Acta Oncol; 2006; 45(8):1041-5. PubMed ID: 17118836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
    Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
    Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
    J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
    Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when.
    Barbaro D; Boni G
    Eur J Surg Oncol; 2007 Jun; 33(5):535-40. PubMed ID: 17337154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
    Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.
    Menzel C; Kranert WT; Döbert N; Diehl M; Fietz T; Hamscho N; Berner U; Grünwald F
    J Nucl Med; 2003 Jul; 44(7):1065-8. PubMed ID: 12843221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer.
    Schlumberger M; Ricard M; De Pouvourville G; Pacini F
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):641-50. PubMed ID: 17710085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of recombinant human TSH for stimulation of iodine radioisotope uptake in metastases of thyroid cancer during therapy with 131I].
    Roskosz J; Handkiewicz-Junak D; Turska M; Wygoda Z; Jurecka-Tuleja B; Jarzab B
    Wiad Lek; 2001; 54 Suppl 1():289-96. PubMed ID: 12182037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients.
    Schlumberger M; Lacroix L; Russo D; Filetti S; Bidart JM
    Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):260-9. PubMed ID: 17315034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.
    Luster M; Sherman SI; Skarulis MC; Reynolds JR; Lassmann M; Hänscheid H; Reiners C
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1371-7. PubMed ID: 12856155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management.
    Chen MK; Doddamane I; Cheng DW
    Curr Opin Oncol; 2010 Jan; 22(1):6-10. PubMed ID: 19844179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
    Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
    Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine therapy of thyroid autonomy.
    Reiners C; Schneider P
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S471-8. PubMed ID: 12192548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective.
    Mernagh P; Suebwongpat A; Silverberg J; Weston A
    Value Health; 2010; 13(2):180-7. PubMed ID: 19818064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation test in the follow-up of thyroid cancer: plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values.
    Zanotti-Fregonara P; Duron F; Keller I; Khoury A; Devaux JY; Hindié E
    Nucl Med Commun; 2007 Apr; 28(4):257-9. PubMed ID: 17325587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer.
    Mallick U; Harmer C; Hackshaw A
    Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):325-6. PubMed ID: 18474322
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.